BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 22339683)

  • 1. Benign apocrine papillary lesions of the breast lacking or virtually lacking myoepithelial cells-potential pitfalls in diagnosing malignancy.
    Cserni G
    APMIS; 2012 Mar; 120(3):249-52. PubMed ID: 22339683
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The usefulness of p63 as a marker of breast myoepithelial cells.
    Batistatou A; Stefanou D; Arkoumani E; Agnantis NJ
    In Vivo; 2003; 17(6):573-6. PubMed ID: 14758723
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diminished number or complete loss of myoepithelial cells associated with metaplastic and neoplastic apocrine lesions of the breast.
    Tramm T; Kim JY; Tavassoli FA
    Am J Surg Pathol; 2011 Feb; 35(2):202-11. PubMed ID: 21263240
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Loss of myoepithelium is variable in solid papillary carcinoma of the breast.
    Nicolas MM; Wu Y; Middleton LP; Gilcrease MZ
    Histopathology; 2007 Nov; 51(5):657-65. PubMed ID: 17927587
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A case of intracystic apocrine papillary tumor: diagnostic pitfalls for malignancy.
    Hayashi H; Ohtani H; Yamaguchi J; Shimokawa I
    Pathol Res Pract; 2013 Dec; 209(12):808-11. PubMed ID: 24095109
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of p63 and CD10 in the differential diagnosis of papillary neoplasms of the breast.
    de Moraes Schenka NG; Schenka AA; de Souza Queiroz L; de Almeida Matsura M; Vassallo J; Alvarenga M
    Breast J; 2008; 14(1):68-75. PubMed ID: 18086274
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sclerosing papillary lesion of the breast: a diagnostic pitfall for malignancy in fine needle aspiration biopsy.
    Saad RS; Kanbour-Shakir A; Syed A; Kanbour A
    Diagn Cytopathol; 2006 Feb; 34(2):114-8. PubMed ID: 16511846
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytologic differential diagnosis of papillary pattern in breast aspirates: correlation with histology.
    Nayar R; De Frias DV; Bourtsos EP; Sutton V; Bedrossian C
    Ann Diagn Pathol; 2001 Feb; 5(1):34-42. PubMed ID: 11172205
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Encapsulated apocrine papillary carcinoma of the breast: case report with clinicopathologic and immunohistochemical study.
    Laforga JB; Gasent JM; Sánchez I
    Diagn Cytopathol; 2011 Apr; 39(4):288-93. PubMed ID: 20734358
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Double immunostaining with p63 and high-molecular-weight cytokeratins distinguishes borderline papillary lesions of the breast.
    Ichihara S; Fujimoto T; Hashimoto K; Moritani S; Hasegawa M; Yokoi T
    Pathol Int; 2007 Mar; 57(3):126-32. PubMed ID: 17295644
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunohistochemical staining of papillary breast lesions.
    Troxell ML; Masek M; Sibley RK
    Appl Immunohistochem Mol Morphol; 2007 Jun; 15(2):145-53. PubMed ID: 17525625
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Papillary neoplasia of the breast: immunohistochemically defined myoepithelial cells in the diagnosis of benign and malignant papillary breast neoplasms.
    Raju UB; Lee MW; Zarbo RJ; Crissman JD
    Mod Pathol; 1989 Nov; 2(6):569-76. PubMed ID: 2479944
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phenotypic alterations in myoepithelial cells associated with benign sclerosing lesions of the breast.
    Hilson JB; Schnitt SJ; Collins LC
    Am J Surg Pathol; 2010 Jun; 34(6):896-900. PubMed ID: 20463570
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Observer variability in the histopathological reporting of core biopsies of papillary breast lesions is reduced by the use of immunohistochemistry for CK5/6, calponin and p63.
    Douglas-Jones A; Shah V; Morgan J; Dallimore N; Rashid M
    Histopathology; 2005 Aug; 47(2):202-8. PubMed ID: 16045782
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Availability of CD10 immunohistochemistry as a marker of breast myoepithelial cells on paraffin sections.
    Moritani S; Kushima R; Sugihara H; Bamba M; Kobayashi TK; Hattori T
    Mod Pathol; 2002 Apr; 15(4):397-405. PubMed ID: 11950913
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mammary lesions diagnosed as "papillary" by aspiration biopsy: 70 cases with follow-up.
    Simsir A; Waisman J; Thorner K; Cangiarella J
    Cancer; 2003 Jun; 99(3):156-65. PubMed ID: 12811856
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of immunohistochemistry in the differential diagnosis of papillary lesions of the breast.
    Tse GM; Tan PH; Moriya T
    J Clin Pathol; 2009 May; 62(5):407-13. PubMed ID: 19126567
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intracystic papillary carcinomas of the breast: a reevaluation using a panel of myoepithelial cell markers.
    Collins LC; Carlo VP; Hwang H; Barry TS; Gown AM; Schnitt SJ
    Am J Surg Pathol; 2006 Aug; 30(8):1002-7. PubMed ID: 16861972
    [TBL] [Abstract][Full Text] [Related]  

  • 19. D2-40 expression by breast myoepithelium: potential pitfalls in distinguishing intralymphatic carcinoma from in situ carcinoma.
    Rabban JT; Chen YY
    Hum Pathol; 2008 Feb; 39(2):175-83. PubMed ID: 18206495
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Myoepithelial cell cocktail (p63+SMA) for the evaluation of sclerosing breast lesions.
    Pavlakis K; Zoubouli C; Liakakos T; Messini I; Keramopoullos A; Athanassiadou S; Kafousi M; Stathopoulos EN
    Breast; 2006 Dec; 15(6):705-12. PubMed ID: 16384708
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.